Peripheral T-Cell Lymphoma Market is Projected to Boost at a Moderate Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Affimed, AstraZeneca, Secura Bio, Dizal, HUYA

February 14 23:56 2023
Peripheral T-Cell Lymphoma Market is Projected to Boost at a Moderate Growth Rate During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Affimed, AstraZeneca, Secura Bio, Dizal, HUYA
Delveinsight Business Research LLP
The Peripheral T-Cell Lymphoma Market therapeutics market is anticipated to evolve immensely in the coming years owing to the ongoing Research and Development (R&D) activities and the active participation of the global pharma and biotech giants in the therapeutic segment. The Peripheral T-Cell Lymphoma (PTCL) pipeline possesses potential drugs in mid-stage developments to be launched in the near future.

The major key players include Viracta Therapeutics, Dizal Pharmaceuticals, Daiichi Sankyo, CStone Pharmaceuticals, Rhizen Pharmaceuticals, Kura Oncology, BeiGene, Celgene Corporation, Innate Pharma, Otsuka Pharmaceutical, Astex Pharmaceuticals, Merck Sharp & Dohme Corp., Bristol Myers Squibb, Affimed, AstraZeneca and others hold the potential to create a significant positive shift in the market outlook.

DelveInsight’s “Peripheral T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Peripheral T-Cell Lymphoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Peripheral T-Cell Lymphoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Peripheral T-Cell Lymphoma Market

Peripheral T-Cell Lymphoma: An Overview

Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called “T cells” and “natural killer (NK) cells.” It is PTCL’s origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term “peripheral” does not refer to the extremities but identifies PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow, such as lymph nodes, spleen, gastrointestinal tract, and skin.

The major types of PTCL include Peripheral T-cell lymphoma (NOS), Anaplastic Large-Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL), and others. 

Peripheral T-Cell Lymphoma Market Key Facts

  • The total Peripheral T-cell Lymphoma market size in the 7MM was USD 564 million in 2021 and is projected to grow during the forecast period (2022-2032).

  • According to the estimates, the largest Peripheral T-cell Lymphoma market size was from the United States in 2021 and is anticipated to grow at a CAGR of 4.9%.

  • Among the EU5 countries, Germany had the maximum revenue share in 2021, while Spain has the lowest market share.

  • The PTCL market size in Japan was USD 193 million in 2021.

  • The total PTCL market size in EU-5 is expected to increase with a CAGR of 4.2% during the study period (2019–2032).

  • The total incident population of PTCL in the 7MM was 18,027 in 2021.

  • The total incident population of PTCL in the United States was 6,366 in 2021. 

  • Japan contributed to the largest incident population of PTCL, accounting for ~ 37% of the 7MM in 2021.

  • Among the EU-5 countries, Germany accounted for the highest number of PTCL cases, followed by France, whereas Spain accounted for the lowest number of cases in 2021. 

Peripheral T-Cell Lymphoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Peripheral T-Cell Lymphoma market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Peripheral T-Cell Lymphoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Peripheral T-Cell Lymphoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Peripheral T-Cell Lymphoma Epidemiology Segmented by –

  • Total Incident Cases of PTCL in the 7MM (2019-2032)

  • Stage-specific Incident Cases of PTCL (2019-2032)

  • Subtype-specific Incident cases of PTCL in (2019-2032)

Peripheral T-Cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Peripheral T-Cell Lymphoma market or expected to be launched during the study period. The analysis covers the Peripheral T-Cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Peripheral T-Cell Lymphoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Peripheral T-Cell Lymphoma Market Will Evolve and Grow by 2032 @

Peripheral T-Cell Lymphoma Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Peripheral T-Cell Lymphomas (PTCL). Currently, HUYA Bioscience International, Shandong New Time Pharmaceutical, Verastem, Genor Biopharma Co., Ltd., Solasia Pharma K.K., CerRx, Inc., Seattle Genetics are some of the leading companies dominating the therapeutic market with their Peripheral T-Cell Lymphomas (PTCL) drug candidates in the mid to advanced stage of clinical development. 

The Leading Companies in the Peripheral T-Cell Lymphomas (PTCL) Market Include:

  • Acrotech Biopharma LLC

  • Affimed

  • Akeso Pharmaceuticals, Inc.

  • Astex Pharmaceuticals

  • AstraZeneca

  • CerRx, Inc.

  • Daiichi Sankyo

  • Dizal Pharmaceuticals

  • Dizal Pharmaceuticals

  • Genor Biopharma Co., Ltd.

  • HUYA Bioscience International

  • Innate Pharma

  • Kura Oncology, Inc.

  • Myeloid Therapeutics

  • Otsuka Pharmaceutical

  • Seattle Genetics, Inc.

  • Secura Bio

  • Shandong New Time Pharmaceutical Co., LTD

  • Shanghai YingLi Pharmaceutical Co. Ltd.

  • Verastem, Inc.

  • Viracta Therapeutics

And Many Others

Peripheral T-Cell Lymphomas (PTCL) Drugs Covered in the Report Include:

  • AFM 13: Affimed

  • AZD4573: AstraZeneca

  • COPIKTRA (Duvelisib): Secura Bio

  • Golidocitinib (DZD4205): Dizal Pharmaceuticals

  • HBI-8000: HUYA Bioscience International

  • Lacutamab: Innate Pharma

  • MT-101: Myeloid Therapeutics

  • Nanatinostat in Combination with Valganciclovir: Viracta Therapeutics

  • Tolinapant (ASTX660): Otsuka Pharmaceutical/Astex Pharmaceuticals

  • Valemetostat Tosylate(DS-3201): Daiichi Sankyo

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Peripheral T-Cell Lymphoma Competitive Intelligence Analysis

4. Peripheral T-Cell Lymphoma Market Overview at a Glance

5. Peripheral T-Cell Lymphoma Disease Background and Overview

6. Peripheral T-Cell Lymphoma Patient Journey

7. Peripheral T-Cell Lymphoma Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Peripheral T-Cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Peripheral T-Cell Lymphoma Unmet Needs

10. Key Endpoints of Peripheral T-Cell Lymphoma Treatment

11. Peripheral T-Cell Lymphoma Marketed Products

12. Peripheral T-Cell Lymphoma Emerging Drugs and Latest Therapeutic Advances

13. Peripheral T-Cell Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Peripheral T-Cell Lymphoma Market Outlook (In US, EU5, and Japan)

16. Peripheral T-Cell Lymphoma Access and Reimbursement Overview

17. KOL Views on the Peripheral T-Cell Lymphoma Market

18. Peripheral T-Cell Lymphoma Market Drivers

19. Peripheral T-Cell Lymphoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Other Trending Healthcare Reports By DelveInsight

Peripheral T-Cell Lymphomas (PTCL) Pipeline Insight

The “Peripheral T-Cell Lymphomas (PTCL) – Pipeline Insight, 2023” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States